ClinicalTrials.Veeva

Menu

Prospective Evaluation of AI-ECG for SHD Detection (AI-ECG-SHD)

Imperial College London logo

Imperial College London

Status

Enrolling

Conditions

Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)
Heart Failure With Reduced Ejection Fraction (HFrEF; Diagnosis)
Valvular Heart Disease Stenosis and Regurgitation (Diagnosis)
Pulmonary Hypertension (Diagnosis)

Treatments

Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram
Other: Apple Watch Series 4 Single-lead Electrocardiogram
Other: Traditional 12-lead Electrocardiogram
Other: Phlebotomy for N-terminal pro-B-type natriuretic peptide
Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

This study aims to improve the early detection of undiagnosed heart disease, which causes serious health issues, hospital admissions, and high healthcare costs. Researchers are exploring how artificial intelligence (AI) can analyse routine heart tests, called electrocardiograms (ECGs), to detect heart problems. These tests can be done using both traditional ECG machines and portable, wearable devices like smartwatches, making it easier for people to monitor their heart health at home.

While AI has shown promise using past data, this study will involve the collection of ECG data and subsequent testing of its accuracy in real-world settings to ensure it works well for both doctors and patients. The goal is to see if AI can identify conditions like heart muscle weakness, valve issues, and high lung pressure from the ECG data of patients. The researchers will also compare AI's detections with other blood tests commonly used to diagnose heart disease.

The AI models that will be used are being tested for research and validation purposes only. They will not be used for clinical decision-making or providing information to influence diagnosis, treatment, or patient care during the study. The AI outputs are not shared with clinicians and will have no impact on the care pathway.

This research will demonstrate if AI-powered ECG analysis - whether from traditional or portable devices - can provide a low-cost, non-invasive way to detect heart disease early and improve health assessments.

Enrollment

590 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients aged 18-90 years
  • No prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
  • Ability to provide informed consent

Exclusion criteria

  • Severe arrhythmia or unstable cardiovascular disease
  • Prior formal diagnosis of HF (including systolic and diastolic dysfunction), PH, or VHD
  • Cardiac implantable electronic device in-situ, including a permanent pacemaker or implantable cardioverter defibrillator
  • Involvement in current research or recent involvement in any research prior to recruitment

Trial design

590 participants in 2 patient groups

Echocardiography cohort
Description:
This cohort of patients will be attending for inpatient and outpatient transthoracic echocardiograms (TTEs) as part of their routine clinical care, having been referred by clinicians for various standard TTE indications, including investigation of symptoms such as breathlessness due to possible heart failure (HF), and screening for suspected valvular heart disease (VHD) and/or pulmonary hypertension (PH). These patients will have had no prior formal diagnosis of HF, VHD, and/or PH.
Treatment:
Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram
Other: Traditional 12-lead Electrocardiogram
Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram
Other: Apple Watch Series 4 Single-lead Electrocardiogram
N-terminal pro B-type natriuretic peptide subgroup
Description:
A subgroup of 203 patients, out of the total 590 patiets in the Echocardiography cohort, will be randomised to undergo blood tests and collection of serum N-terminal pro B-type natriuretic peptide (NT-proBNP).
Treatment:
Other: AliveCor KardiaMobile Single- and 6-lead Electrocardiogram
Other: Phlebotomy for N-terminal pro-B-type natriuretic peptide
Other: Traditional 12-lead Electrocardiogram
Other: Eko Core 500 Digital Stethoscope 3-lead Electrocardiogram
Other: Apple Watch Series 4 Single-lead Electrocardiogram

Trial contacts and locations

2

Loading...

Central trial contact

Ahmed YM El-Medany, MBChB, MRCP, MSc, FHEA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems